Salarius Pharmaceuticals Inc (SLRX): Price and Financial Metrics

Salarius Pharmaceuticals Inc (SLRX): $0.49

0.01 (+1.71%)

POWR Rating

Component Grades

Momentum

F

Stability

D

Sentiment

Quality

D

Add SLRX to Watchlist
Sign Up

SLRX Price/Volume Stats

Current price $0.49 52-week high $2.31
Prev. close $0.48 52-week low $0.43
Day low $0.48 Volume 6,200
Day high $0.52 Avg. volume 101,241
50-day MA $0.57 Dividend yield N/A
200-day MA $0.71 Market Cap 2.13M

SLRX Stock Price Chart Interactive Chart >


Salarius Pharmaceuticals Inc (SLRX) Company Bio


Salarius Pharmaceuticals Inc is a clinical-stage oncology company. The Company specializes in targeting the epigenetic causes of cancers and developing treatments for patients. Salarius Pharmaceuticals serves patients and customers in the State of Texas.


SLRX Latest News Stream


Event/Time News Detail
Loading, please wait...

SLRX Latest Social Stream


Loading social stream, please wait...

View Full SLRX Social Stream

Latest SLRX News From Around the Web

Below are the latest news stories about SALARIUS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate SLRX as an investment opportunity.

SLRX Continues Work as it Seeks Alternatives

By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Earnings Update • Salarius (NASDAQ:SLRX) announced a 3Q loss of $0.65 per share, compared to a $6.41 per share loss in the same quarter in 2022. • Cash and cash equivalents were $7.6 million at the end of 3Q, compared to $12.1 million at the end of 2022. Update Salarius Pharmaceuticals recently announced that it was exploring

Yahoo | November 10, 2023

Salarius Completes FDA Type B Meeting for Seclidemstat Ewing Sarcoma Development Program

FDA briefing included new Ewing sarcoma clinical data from ongoing investigation where 60% of first-relapse patients achieved disease control and have not progressed after at least 14.5, 19.7 and 22.8 months Future development activities were identified; Salarius intends to submit an amended Ewing sarcoma clinical trial protocol HOUSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announces that it participated in a Type B End-of-Phase 2 (EOP2) meeting with th

Yahoo | November 7, 2023

Salarius Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides a Business Update

FDA removed partial clinical hold for Ewing sarcoma Phase 1/2 study with seclidemstat SP-3164 targeted protein degrader received Investigational New Drug clearance from FDA Company to explore strategic alternatives and implement measures to extend its resources HOUSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new

Yahoo | August 10, 2023

SLRX Pursuing Strategic Alternatives

By Brad Sorensen, CFA NASDAQ:SLRX READ THE FULL SLRX RESEARCH REPORT Salarius Pharmaceuticals (NASDAQ:SLRX) recently announced that it was exploring “strategic alternatives” and cutting costs in order to extend its resources. We are disappointed in this announcement as we continue to believe in the science behind the treatments being developed by Salarius. However, we understand that funding has

Yahoo | August 9, 2023

Salarius Pharmaceuticals Announces Plans to Explore Strategic Alternatives and Implement Measures to Extend its Resources

HOUSTON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced plans to explore strategic alternatives and implement measures to extend its resources. “The second quarter and recent weeks were highlighted by significant advancements in both of our development programs, but after a review o

Yahoo | August 8, 2023

Read More 'SLRX' Stories Here

SLRX Price Returns

1-mo -20.97%
3-mo -10.09%
6-mo -32.97%
1-year -71.35%
3-year -98.35%
5-year -99.86%
YTD -24.62%
2023 -57.52%
2022 -87.65%
2021 -45.54%
2020 -75.93%
2019 -54.18%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!